Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | SCD | O00767 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.35 |
| ▸ | PDE5A | O76074 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3618266 | 0.78 | HDAC6 (0.35) | GAALMNAKDM4EALDH1A1HDAC3 | |
| SCHEMBL3604245 | 0.77 | MEN1 (0.46) | MAPTLMNAHTTSMN1; SMN2MEN1 | |
| SCHEMBL3604443 | 0.77 | MEN1 (0.41) | MAPTGAALMNAHTTKDM4E | |
| SCHEMBL3602427 | 0.77 | HDAC6 (0.38) | HDAC3HDAC1PDE5A | |
| SCHEMBL3604448 | 0.74 | KDM4E (0.38) | MAPTGAALMNAKDM4ESMN1; SMN2 | |
| SCHEMBL3607234 | 0.72 | HDAC3 (0.45) | MAPTGAALMNAHTTKDM4E | |
| SCHEMBL3608603 | 0.70 | HDAC3 (0.42) | MAPTGAALMNAKDM4ESMN1; SMN2 | |
| SCHEMBL3609508 | 0.70 | GSTO1 (0.47) | MAPTGAALMNAHTTALDH1A1 | |
| SCHEMBL3597144 | 0.70 | SMN1; SMN2 (0.57) | MAPTGAALMNAKDM4ESMN1; SMN2 | |
| SCHEMBL3607165 | 0.69 | PKM (0.42) | MAPTGAALMNAHTTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100152188-A1 | Novel Heterocyclic Compounds | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2010-06-17 | — | — | US | claimed |
| US-20100152188-A1 | Novel Heterocyclic Compounds | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152188-A1 | Novel Heterocyclic Compounds | CYP11B2, CYP3A5, CYP11B1 | MAPT 2986/4885GAA 325/4885LMNA 3772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.